Compare
QuidelOrtho Corp vs Idexx Laboratories Inc vs Lantheus Holdings, Inc. vs Volitionrx Ltd
| Latest fiscal year | QuidelOrtho Corp QDEL | Idexx Laboratories Inc IDXX | Lantheus Holdings, Inc. LNTH | Volitionrx Ltd VNRX |
|---|---|---|---|---|
| Year ended | 2025-12-28 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.73B | $4.30B | $1.54B | $1.73M |
| Revenue growth (YoY) | -1.9% | +10.4% | +0.5% | +40.0% |
| Gross margin | n/a | 61.8% | 61.1% | n/a |
| Operating margin | -33.7% | 31.6% | 20.2% | n/m |
| Net margin | -41.5% | 24.6% | 15.2% | n/m |
| Net income | -$1.13B | $1.06B | $233.56M | -$23.36M |
| EPS (Diluted) | -$16.69 | $13.08 | $3.41 | n/a |
| Operating cash flow | $105.20M | $1.18B | $390.14M | -$19.68M |
| Free cash flow | -$83.00M | $1.06B | n/a | -$19.77M |
| Cash & equivalents | $169.80M | $180.07M | $359.12M | $1.12M |
| Total assets | $5.77B | $3.35B | $2.23B | $6.90M |
| Total liabilities | $3.85B | $1.75B | $1.14B | $42.49M |
| Shareholders' equity | $1.92B | $1.61B | $1.09B | -$34.25M |
| Return on year-end equity | -58.9% | 66.0% | 21.4% | n/a |
| Shares outstanding | 67.90M | 79.71M | 64.59M | 125.78M |
Revenue, most recent five fiscal years
| Fiscal year | QuidelOrtho Corp | Idexx Laboratories Inc | Lantheus Holdings, Inc. | Volitionrx Ltd |
|---|---|---|---|---|
| Latest | $2.73B Ended 2025-12-28 | $4.30B Ended 2025-12-31 | $1.54B Ended 2025-12-31 | $1.73M Ended 2025-12-31 |
| 1 year earlier | $2.78B Ended 2024-12-29 | $3.90B Ended 2024-12-31 | $1.53B Ended 2024-12-31 | $1.23M Ended 2024-12-31 |
| 2 years earlier | $3.00B Ended 2023-12-31 | $3.66B Ended 2023-12-31 | $1.30B Ended 2023-12-31 | $775.3K Ended 2023-12-31 |
| 3 years earlier | $3.27B Ended 2023-01-01 | $3.37B Ended 2022-12-31 | $935.06M Ended 2022-12-31 | $306.4K Ended 2022-12-31 |
| 4 years earlier | $1.70B Ended 2022-01-02 | $3.22B Ended 2021-12-31 | $425.21M Ended 2021-12-31 | $90.0K Ended 2021-12-31 |